Hexarelin
Hexarelin (Examorelin) is arguably the most potent synthetic Growth Hormone Secretagogue (GHRP) ever developed. Clinically unique among GHRPs, it exhibits profound cardioprotective properties, mitigating left ventricular dysfunction and ischemic injury independent of Growth Hormone release. While it forces an immense, immediate GH spike—often superseding even GHRP-2—it is notorious for rapid receptor desensitization, meaning cycles must be strictly capped at 4 to 6 weeks before efficacy plummets.
Quick Stats
Scientific Data
Mechanism of Action
Hexarelin is the most potent ghrelin receptor agonist in the GHRP family, producing the strongest GH release pulse. However, it is also the most non-selective, causing significant elevations in cortisol and prolactin. Uniquely, Hexarelin has documented cardioprotective properties — it directly protects cardiac tissue through mechanisms independent of GH release.
The major limitation of Hexarelin is desensitization: continuous use beyond approximately 4 weeks leads to diminishing GH response as receptors downregulate. This necessitates cycling protocols.
Source: PMID: 12165110
Background & History
Hexarelin is a synthetic hexapeptide GHRP developed by Europeptides (France) in the 1990s. It is the most potent GHRP known, producing the largest GH pulses of any peptide in its class. Uniquely, Hexarelin also independently stimulates the release of cortisol and prolactin more than any other GHRP and shows cardiovascular cardioprotective properties independent of GH — binding to cardiac CD36 receptors to reduce ischemic damage. This dual GH+cardiac mechanism is the subject of ongoing research.
Research Use Cases
- ✓Maximum-potency GH stimulation for short-term anabolic cycles
- ✓Cardiovascular protection and post-infarction cardiac repair (independent of GH)
- ✓Evaluation of pituitary GH reserve (diagnostic)
Dosing Protocol
| Typical Dose | 100-200 mcg/injection |
| Frequency | 1-2× daily |
| Half-Life | ~70 minutes |
| Common Vial Sizes | 2 mg, 5 mg |
Dosing Protocols
Standard Protocol (4-week cycle)
Body-Weight Dosing Reference
Estimated doses extrapolated from the published research range of 100–200 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.
| Weight | Low Dose | Target Dose | High Dose |
|---|---|---|---|
| 120 lb(54 kg) | 77 mcg | 116 mcg | 154 mcg |
| 140 lb(63 kg) | 90 mcg | 135 mcg | 180 mcg |
| 160 lb(73 kg) | 104 mcg | 156 mcg | 209 mcg |
| 180 lb(82 kg) | 117 mcg | 176 mcg | 234 mcg |
| 200 lb(91 kg) | 130 mcg | 195 mcg | 260 mcg |
| 220 lb(100 kg) | 143 mcg | 214 mcg | 286 mcg |
| 250 lb(113 kg) | 161 mcg | 242 mcg | 323 mcg |
💉 For exact syringe units based on your vial concentration, use the Hexarelin Reconstitution Calculator →
Administration
Expected Timeline
Who Is It For?
Short-Burst GH Maximization
HighMost potent GHRP GH pulse in brief 4-week cycles before desensitization.
Cardiac Health
ModerateDocumented cardioprotective effects independent of GH release via CD36 receptor.
Reconstitution Example
Safety & Considerations
Research peptide. Subject to receptor desensitization — cycle 4 weeks on, 2-4 weeks off. Significantly elevates cortisol and prolactin. Has cardioprotective properties independent of GH.
Regulatory & Legal Status
Competitive athletes subject to anti-doping controls should not use Hexarelin.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
Significant cortisol and prolactin elevation with chronic use. Desensitizes GHS-R1a faster than other GHRPs — limit continuous use to 4 weeks. Contraindicated in prolactin-sensitive conditions (e.g., prolactinoma). Not for use during active cancer treatment.
Synergies & Common Stacks
Produces the highest combined GH release of any GHRH+GHRP combination. Reserve for aggressive short-term protocols due to desensitization risk.
Dosing Quick Reference
Frequently Asked Questions
Why does Hexarelin cause desensitization?▼
What is the Hexarelin dose?▼
References
- Deghenghi et al. “"Hexarelin, a new GH-releasing peptide".” Life Sciences (1994). PMID: 8164528
📚 Related Articles
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code